Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tempest Therapeutics Inc (NQ: TPST )

0.7935 -0.0411 (-4.92%)
Streaming Delayed Price Updated: 12:51 PM EST, Dec 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tempest Therapeutics Inc

< Previous 1 2 3 Next >
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference
From Tempest Therapeutics
Via GlobeNewswire
“Market Mavericks: Stocks Creating Ripples of Success” CLNV, TPST, HNRC, INPX
Via AB Newswire
Intelligent Bio (NASDAQ: INBS) Surges Massively Among Stocks Making BUZZ:TPST, HNST, LTRN, VTAK
Via AB Newswire
Exposures Product Safety
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
MarketBeat Week in Review – 10/16 - 10/20
All the major indexes moved lower on Friday, making it a near certainty that stocks would post their worst week in a month; the bears are firmly in control 
Via MarketBeat
Topics Bonds Economy
Exposures Debt Markets Economy Interest Rates
The Secrets Behind a 4000% Biotech Stock Surge
Last Wednesday, shares of Tempest Therapeutics (NASDAQ: TPST), a small-cap stock you have probably never heard of, surged over 4000%. 
Via MarketBeat
Exploring What Led to a 3,000% Surge in Shares of Tempest Therapeutics (NASDAQ: TPST)
Tempest Therapeutics, Inc. (NASDAQ: TPST) recently captivated investors with an unprecedented surge of over 3,000% in less than a week. 
Via Spotlight Growth
Tempest Adopts Limited Duration Stockholder Rights Plan
From Tempest Therapeutics
Via GlobeNewswire
Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study
From Tempest Therapeutics
Via GlobeNewswire
Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
Webcasted Conference Call on Wednesday, October 11, 2023 at 8:30 a.m. ET 
From Tempest Therapeutics
Via GlobeNewswire
Navigating the Roller Coaster of Recent Penny Stock Surges
Recent surges in penny stocks, like Secoo (SECO), Tempest Therapeutics (TPST), and OpGen (OPGN), have fueled speculation and excitement in penny stocks. 
Via MarketBeat
Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development
From Tempest Therapeutics
Via GlobeNewswire
Tempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Tempest Therapeutics
Via GlobeNewswire
Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together
From Tempest Therapeutics
Via GlobeNewswire
Tempest to Present at the Jefferies Global Healthcare Conference
From Tempest Therapeutics
Via GlobeNewswire
Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers
From Tempest Therapeutics
Via GlobeNewswire
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tempest Reports First Quarter 2023 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tempest Therapeutics (NASDAQ: TPST) Reports Strong Early Results From Phase 1b/2 Study of TPST-1120 in Hepatocellular Carcinoma
Tempest Therapeutics, Inc. (NASDAQ: TPST) is engaged as a clinical-stage oncology company, which is focused on the research and development 
Via Spotlight Growth
Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
From Tempest Therapeutics
Via GlobeNewswire
Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
Webcast Conference Call Friday, April 28, 2023, at 8:30 a.m. ET 
From Tempest Therapeutics
Via GlobeNewswire
Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
Tempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
Tempest Reports Year End 2022 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tempest to Present Biomarker Data for TPST-1120 at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific Meeting
From Tempest Therapeutics
Via GlobeNewswire
Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference
From Tempest Therapeutics
Via GlobeNewswire
Tempest Presents Data Showing TPST-1120-Induced Pharmacodynamic Changes Consistent with Clinical Benefit Observed in Patients with Cancer
From Tempest Therapeutics
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback